Browsing Centre for Genomics and Child Health by Author "Valdes, AM"
Now showing items 1-6 of 6
-
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
Abhishek, A; Peckham, N; Pade, C; Gibbons, JM; Cureton, L; Francis, A; Barber, V; Williams, JAE; Appelbe, D; Eldridge, L (2024-02)BACKGROUND: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 ... -
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Abhishek, A; Boyton, RJ; Peckham, N; McKnight, A; Coates, LC; Bluett, J; Barber, V; Cureton, L; Francis, A; Appelbe, D (2022) -
HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19
Astbury, S; Reynolds, CJ; Butler, DK; Munoz-Sandoval, DC; Lin, K-M; Pieper, FP; Otter, A; Kouraki, A; Cusin, L; Nightingale, J (2022) -
Longitudinal assessment of symptoms and risk of SARS-CoV-2 infection in healthcare workers across 5 hospitals to understand ethnic differences in infection risk.
Valdes, AM; Moon, JC; Vijay, A; Chaturvedi, N; Norrish, A; Ikram, A; Craxford, S; Cusin, LML; Nightingale, J; Semper, A (2021) -
Steroid receptor coactivator-1 modulates the function of Pomc neurons and energy homeostasis
Yang, Y; van der Klaauw, AA; Zhu, L; Cacciottolo, TM; He, Y; Stadler, LKJ; Wang, C; Xu, P; Saito, K; Hinton, A (2019-04-12) -
The UK10K project identifies rare variants in health and disease
Walter, K; Min, JL; Huang, J; Crooks, L; Memari, Y; McCarthy, S; Perry, JRB; Xu, C; Futema, M; Lawson, D (2015-10-01)